Ann: Notice of Annual General Meeting/Proxy Form, page-14

Hi Redant,

I don’t place too much emphasis on the comments around Hernia and Dura Mattar. The point is I suppose that we have those possibilities up up our sleeve for when the right time and funding permits.

With LeMaitre selling our products already we could do a further distribution deal for ancillary products that we produce in future. I know we are working on more than just the valve in the heart space and I suspect the new FDA clearance opens up possibilities like CABAG that has long been on our development list.

While the DurAVR may seem like a single product it will have iterations and it’s use in both the SAVR market and the TAVR market will offer two distinct business possibilities.

In the background we still have the ability to manufacture other products (to licence) as you point out which gives us good optionality.

DYOR and Not advice